About Delfi Diagnostics
Delfi Diagnostics is a company based in Baltimore (United States) founded in 2019. Delfi Diagnostics has raised $331.59 million across 6 funding rounds from investors including Lilly, Brown Advisory and TD Securities. Delfi Diagnostics offers products and services including DELFI Method and CASCADE-LUNG Trial. Delfi Diagnostics operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter Baltimore, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Delfi Diagnostics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$331.59 M (USD)
in 6 rounds
-
Latest Funding Round
$34.33 M (USD), Debt – Conventional
Dec 01, 2025
-
Investors
Lilly
& 18 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Delfi Diagnostics
Delfi Diagnostics offers a comprehensive portfolio of products and services, including DELFI Method and CASCADE-LUNG Trial.
Analyzes cell-free DNA fragments for early cancer screening.
Evaluates fragmentomics technology for lung cancer detection.
People of Delfi Diagnostics
Unlock access to complete
Unlock access to complete
Software Development Team
27 people
Leadership Team
15 people
Advisor Team
8 people
Senior Team
8 people
Board Team
5 people
Product Management Team
5 people
Staff Team
4 people
Data Analysis and Operations Team
4 people
Unlock access to complete
Funding Insights of Delfi Diagnostics
Delfi Diagnostics has successfully raised a total of $331.59M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $34.33 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Delfi Diagnostics
Delfi Diagnostics has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Brown Advisory and TD Securities.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are directed toward innovative technology startups by DFJ Growth.
|
Locked | Locked | Locked | |
|
No specific business activity is described for this entity.
|
Locked | Locked | Locked | |
|
PTX Capital is involved in capital investment activities.
|
Locked | Locked | Locked |
Investor details for Delfi Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Delfi Diagnostics
Investment portfolio details for Delfi Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Delfi Diagnostics
Detailed financials for Delfi Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Delfi Diagnostics Comparisons
Peer comparison for Delfi Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Delfi Diagnostics
Delfi Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Delfi Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Delfi Diagnostics
Complete news archive for Delfi Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Delfi Diagnostics
Delfi Diagnostics was founded in 2019.
Delfi Diagnostics is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Susan Tousi is the current CEO of Delfi Diagnostics.
Delfi Diagnostics is a funded company, having raised a total of $331.59M across 6 funding rounds to date.
Delfi Diagnostics was founded in 2019 and is based in Baltimore, United States. Operations focus on the biotechnology sector, where a platform employing artificial intelligence and whole genome sequencing is utilized to identify DNA fragmentation patterns in patient blood samples. Services are centered on early cancer detection through non-invasive liquid biopsy methods, supporting diagnostic applications in oncology.
Delfi Diagnostics's top competitors include Guardant Health, GRAIL and Foundation Medicine.
Delfi Diagnostics offers DELFI Method and CASCADE-LUNG Trial.
Delfi Diagnostics has 19 investors. Key investors include Lilly, Brown Advisory, TD Securities, Orbimed, and DFJ Growth.